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Abstract Heart failure following acute myocardial
infarction (AMI) is a major cause of morbidity and mor-
tality. Our previous observation that injection of apoptotic
peripheral blood mononuclear cell (PBMC) suspensions
was able to restore long-term cardiac function in a rat AMI
model prompted us to study the effect of soluble factors
derived from apoptotic PBMC on ventricular remodelling
after AMI. Cell culture supernatants derived from irradi-
ated apoptotic peripheral blood mononuclear cells (APO-
SEC) were collected and injected as a single dose
intravenously after myocardial infarction in an experi-
mental AMI rat model and in a porcine closed chest rep-
erfused AMI model. Magnetic resonance imaging (MRI)
and echocardiography were used to quantitate cardiac
function. Analysis of soluble factors present in APOSEC
was performed by enzyme-linked immunosorbent assay
(ELISA) and activation of signalling cascades in human
cardiomyocytes by APOSEC in vitro was studied by
immunoblot analysis. Intravenous administration of a sin-
gle dose of APOSEC resulted in a reduction of scar tissue
formation in both AMI models. In the porcine reperfused
AMI model, APOSEC led to higher values of ejection
fraction (57.0 vs. 40.5%, p\0.01), a better cardiac output
(4.0 vs. 2.4 l/min, p\0.001) and a reduced extent of
infarction size (12.6 vs. 6.9%, p\0.02) as determined by
MRI. Exposure of primary human cardiac myocytes with
APOSEC in vitro triggered the activation of pro-survival
signalling-cascades (AKT, Erk1/2, CREB, c-Jun),
increased anti-apoptotic gene products (Bcl-2, BAG1)
and protected them from starvation-induced cell death.
Intravenous infusion of culture supernatant of apoptotic
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AMI models. This effect is probably due to the activa-
tion of pro-survival signalling cascades in the affected
cardiomyocytes.
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Introduction
Although prompt reperfusion within a narrow time window
has signiﬁcantly reduced early mortality following acute
myocardial infarction (AMI), ischaemic heart failure
remains widely prevalent and represents an increasing
economic burden [42]. A new ﬁeld in regenerative car-
diovascular medicine emerged when investigators observed
that distant stem cells were able to sense sites of damage
and promote structural and functional repair after experi-
mental myocardial infarction [6, 9, 10, 17, 29, 31, 38, 44].
This experimental insight into regeneration following AMI
triggered the start of randomized, controlled clinical trials
demonstrating that cell therapy could improve cardiac
function in patients after AMI [14, 27, 36, 43]. In 2005,
Thum et al. established ‘‘The Dying Stem Cell Hypothe-
sis’’, namely, that therapeutic stem cells are already
undergoing apoptosis while being infused into the infarcted
area, thereby attenuating infarction-induced immunoacti-
vation and remodelling via the induction of immunomod-
ulatory mechanisms [33, 34, 39].
We have previously shown that infusion of cultured
irradiated apoptotic peripheral blood mononuclear cell
(PBMC) suspensions in a rat acute AMI model caused
homingofregenerativeFLK?/c-kit?cellsintheearlyphase
of experimental AMI and restored long-term cardiac func-
tion[2,26].Incontrast, infusionofculturedviablePBMCin
the same setting had only marginal efﬁcacy in preservation
of cardiac function. Moreover, we found that induction of
apoptosis in PBMC led to the massive secretion of Inter-
leukin-8 (IL-8) and Matrixmetalloproteinase 9 (MMP9)
proteins known to be responsible for neo-angiogenesis and
recruitment of pro-angiogenic cells from the bone marrow
(BM) to the infarcted myocardium [20, 24, 28].
Our data suggest two possible causes for this in vivo
regenerative effect. Either infusion of apoptotic PBMC
reduces the immune response after AMI by deﬁned
mechanisms [4, 34] or soluble factors secreted by apoptotic
PBMC cause induction of neo-angiogenesis and cytopro-
tection in the acute phase of myocardial infarction. This
latter speculation is supported by the recent publications
providing evidence that bone marrow cells or endothelial
progenitor cells secrete soluble proteins which induce
regenerative mechanisms in a paracrine manner [7, 13, 25].
Having shown that infusion of apoptotic PBMC sus-
pensions in an acute rat AMI model prevented ventricular
remodelling, we investigated whether simply administering
soluble factors derived from irradiated PBMC (APOSEC;
this acronym stands for apoptotic secretome) showed
similar properties and caused cardioprotection in the same
acute rat AMI model. To further strengthen the clinical
relevance of APOSEC, we tested this ‘‘biological’’ in cell
cultures of cardiac myocytes in vitro and in a porcine
closed chest reperfused AMI model in vivo. Here we
provide evidence that APOSEC confers cytoprotection
directly to cardiac myocytes, and that intravenous appli-
cation of APOSEC is effective in preventing myocardial
damage and tissue remodelling in a dose-dependent man-
ner in the porcine reperfused AMI model.
Methods
Generation of cell culture medium derived
from irradiated human apoptotic PBMC (APOSEC
H)
for in vitro assays
Human PBMC were obtained from young healthy volun-
teers after informed consent (ethics committee vote: EK-Nr
2010/034). Cells were separated by Ficoll-Paque (GE
Healthcare Bio-Sciences AB, Sweden) density gradient
centrifugation as described previously [2]. Apoptosis of
PBMC was induced by Caesium-137 irradiation (Depart-
ment of Transfusion Medicine, General Hospital Vienna)
with 60 Gray (Gy) for in vitro experiments. Induction of
apoptosis was measured by Annexin-V/propidium iodine
(FITC/PI) co-staining (Becton–Dickinson, Franklin Lakes,
NJ, USA) on a ﬂow cytometer. Irradiated and non-irradi-
ated cells were resuspended in serum-free UltraCulture
Medium (Lonza, Switzerland) and cultured for 24 h in
various cell densities (1 9 10
6, 2.5 9 10
6 and 25 9 10
6
cells/ml, n = 5). After 24 h supernatants were collected
and served as experimental entities for ELISA content
analysis or were lyophilized as follows: supernatants were
dialyzed against ammonium acetate (at a concentration of
50 mM) for 24 h at 4C. The obtained liquid was sterile
ﬁltered (Whatman Filter 0.2 lm FP30/o,2 Ca–S, Dassel,
Germany), frozen and lyophilized overnight (Lyophilizator
Christ alpha 1-4, Martin Christ Gefriertrocknungsanlagen
GmbH, Osterode am Harz, Germany) (Fig. 1).
To avoid possible cross-species detrimental immune
reactions, we opted to utilize APOSEC preparations solely
in a syngeneic fashion.
For in vivo rat experiments, syngeneic rat PBMC were
separated by density gradient centrifugation from whole
blood obtained from heparinized rats. PBMC were irradi-
ated by Caesium-137 (45 Gy) and cultured for 24 h at a
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123cell density of 25 9 10
6 cells/ml (in UltraCulture Medium,
Lonza, Switzerland). APOSEC for rat experiments (APO-
SEC
R) was further processed as described for APOSEC
H.
Supernatants of non-irradiated rat PBMC served as
controls.
For large animal experiments, blood was obtained from
anaesthetized pigs by direct heart puncture. Three pigs
were anaesthetized with an IV bolus of 10 mg/kg ketamine
and 1.3 mg/kg azaperone and a left thoracic dermal inci-
sion was conducted. Direct heart puncture was then per-
formed under sterile conditions using a hollow needle and
blood was drawn with 50-ml syringes. Blood obtained
during this procedure was transferred into heparinized
plastic bags for blood products. PBMC were then obtained
according to the protocol described above. CellGro
 DC
serum-free medium (CellGenix GmbH, Freiburg, Ger-
many), a ‘‘Good Manufacturing Practice’’ certiﬁed culture
medium, was utilized for porcine PBMC-derived APOSEC
production (APOSEC
P). APOSEC for porcine experiments
(APOSEC
P) was processed as described for APOSEC
H.
APOSEC
H content evaluation by membrane arrays
and ELISA analysis
APOSEC
H was screened for cytokines and angiogenic
factors using two commercially available array systems
(Proteome Proﬁler Arrays, R&D Systems, Minneapolis,
USA). Supernatant levels of cytokines secreted by irradi-
ated and non-irradiated PBMC in various concentrations
were measured by utilizing commercially available
enzyme-linked immunosorbent assay (ELISA, Duoset,
R&D Systems, Minneapolis, USA) kits for the quantiﬁca-
tion of IL-8, GRO-a, ENA-78, VEGF, IL-16, IL-10, TGF-
b, sICAM-1, RANTES, IL-1ra, MIF, PAI-1, IGF-I, HGF,
FGF-2, MCP-1, MMP9, SDF-1, G-CSF, GM-CSF and
HMGB1 (IBL International GmbH, Hamburg, Germany).
Study design for rat experiments (acute myocardial ischaemia model) (b)
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Fig. 1 Study design: a The preparation process of APOSEC, starting
with cell separation, induction of apoptosis, cell culture, dialysis,
lyophilization and its use in in vitro and in vivo experiments is shown.
b Study design for in vivo rat experiments. A permanent ligation of
the LAD was conducted in male Sprague–Dawley rats, initially
thereafter APOSEC
R, supernatant derived from non-irradiated cells or
control medium was injected intravenously into the femoral vein.
Evaluations by immunohistology and ﬂow cytometry were performed
3 days after LAD ligation. Planimetric analysis and echocardiography
were conducted 6 weeks after MCI. c Experimental setting of closed
chest reperfused AMI in a porcine model. Ischaemia was induced by
balloon occlusion of the LAD for 90 min. 40 min after balloon
inﬂation, APOSEC
P was administered intravenously. Cardiac MRI
evaluations were performed 3 and 30 days after AMI
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R treatment
Animal experiments were approved by the committee for
animal research, Medical University of Vienna (vote:
66.009/0168-II/10b/2008). Acute myocardial infarction
was induced in adult male Sprague–Dawley rats (weight
275–300 g) by ligating the LAD. A left lateral thoracotomy
was performed and a ligature using 6-0 prolene was placed
around the LAD beneath the left atrium. Immediately after
the onset of ischaemia, lyophilized supernatants obtained
from 8.5 9 10
6 either irradiated apoptotic PBMC or non-
irradiated viable cells resuspended in 0.3 ml fresh Ultra-
Culture Medium (Lonza, Basel, Switzerland) were injected
in the femoral vein. Injection of cell culture medium alone
and sham operation served as controls.
Rat immunohistochemistry and determination
of myocardial infarction size by planimetry
All animals were sacriﬁced either 72 h or 6 weeks after
experimental infarction. Hearts were explanted and then
sliced into three layers at the level of the largest extension of
infarcted area (n = 6 for 72 h analyses, n = 9 for 6 weeks
analyses). The tissue samples were stained with hematox-
ylin–eosin (H&E) and Elastica van Gieson (EVG). Short-
term immunohistological evaluation (72 h) was performed
using antibodies directed to CD68 (MCA341R, AbD
Serotec, Kidlington, UK) and c-kit (sc-168, Santa Cruz
Biotechnology, CA, USA). Image J planimetry software
(Rasband, W.S., Image J, U.S. National Institutes of Health,
Bethesda, USA) was utilized to determine the size of
myocardial infarct after 6 weeks.
Flow cytometry analysis, homing of CD68?
and c-kit? cells
Three days after myocardial infarction, rats treated with
either APOSEC
R, viable cell derived supernatant or control
medium were sacriﬁced. Infarcted areas of explanted hearts
were cut into small cubes (1 mm) and incubated with col-
lagenase (2.4 U/ml, Sigma, St Louis, Mo) for 12 h at 4C.
After digestion and washing, the cells were incubated with
primary antibodies directed to CD68 (MCA341R, AbD
Serotec, Kidlington, UK) and c-kit (sc-168, Santa Cruz
Biotechnology, CA, USA). After an incubation period with
a secondary antibody, cell suspensions were analysed for
total CD68? and c-kit? cell numbers by ﬂow cytometry
(FACS Calibur, Becton–Dickinson, Franklin Lakes, USA).
Rat cardiac function assessment by echocardiography
Sixweeksafterinductionofmyocardialinfarction,ratswere
anaesthetized with 100 mg/kg ketamine and 20 mg/kg
xylazine. The sonographic examination was conducted on a
Vivid 7 system (General Electric Medical Systems, Wau-
kesha, USA). Analyses were performed by an experienced
observer blinded to the treatment groups to which the ani-
mals were allocated. M-mode tracings were recorded from a
parasternal short-axis view and functional systolic and dia-
stolic parameters were obtained. Fractional shortening was
calculated as follows: FS (%) = ((LVEDD - LVESD)/
LVEDD) 9 100%, where LVEDD and LVESD mean left
ventricular end-diastolic and end-systolic diameter,
respectively.
Porcine closed chest reperfused infarction model
and APOSEC
P
A closed chest reperfused AMI infarction model was
applied in a large animal setting [15, 16]. The experiments
in the porcine infarction model were carried out at the
Institute of Diagnostics and Oncoradiology, University of
Kaposvar, Hungary. Animal experiments were approved by
the University of Kaposvar (vote: 246/002/SOM2006,
MAB-28-2005). After overnight fasting, the pigs (female
Large Whites weighing approximately 30 kg) were sedated
with 12 mg/kg ketamine hydrochloride, 1.0 mg/kg xyla-
zine and 0.04 mg/kg atropine. After the administration of
200 IU/kg of heparin, a 6F guiding catheter (Medtronic
Inc., Minneapolis, USA) was introduced into the left cor-
onary ostium, and selective angiography of the left coro-
nary arteries was performed using Ultravist contrast
medium (Bayer Healthcare, Berlin, Germany). A Maverick
balloon catheter (diameter: 3.0 mm, length: 15 mm; Bos-
ton Scientiﬁc, Natick, USA) was inserted into the left
anterior descending artery (LAD) after the origin of the
second major diagonal branch. The LAD was then occlu-
ded by inﬂating the balloon slowly at 4–6 atm (n = 8i n
the control group, n = 7 in the treatment high dose and
n = 7 in the treatment low-dose group), controlling the
occlusion with angiography. Forty minutes after the start of
the LAD occlusion, the lyophilized supernatant obtained
from 250 9 10
6 (low-dose group), 1 9 10
9 (high-dose
group) irradiated apoptotic porcine PBMC or lyophilized
serum-free cell culture medium (CellGro
 DC, CellGenix
GmbH, Freiburg, Germany) was resuspended in 250 ml of
0.9% physiologic sodium chloride solution and adminis-
tered intravenously over the next 25 min. After 90 min of
occlusion, the balloon was deﬂated and reperfusion was
established. Control coronary angiography was performed
to prove the patency of the infarct-related artery and to
exclude arterial injury. Furthermore, all animals received
75 mg clopidogrel and 100 mg acetylsalicylic acid. After
24 h or after 30 days, euthanasia was performed by the
administration of saturated potassium chloride. For the
analysis conducted after 24 h, in situ double-staining with
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1231% Evans blue dye and a 4% solution of 2,3,5-triphenyl-
tetrazolium chloride (TTC) was performed to delineate
areas at risk for ischaemia and infarcted (necrotic) areas,
respectively. In short, after explantation the LAD was
occluded again at same position where the balloon was
situated before and both coronary arteries were perfused
with Evans blue solution to delineate the area at risk and
non-risk region. The hearts were cut into 7 mm thick slices
starting from the apex towards the level of the occlusion
(6–7 layers per heart). The slices were incubated in 500 ml
of TTC solution at 37C in a shaking water bath for
20 min. Subsequently, all slices underwent an overnight
bleach cycle at room temperature using 4.5% formalde-
hyde. All slices were photographed using a digital camera
(Panasonic HDC-HS700, Osaka, Japan) mounted on a ﬁxed
stand. Planimetry was performed using Image J software
(Rasband, W.S., Image J, US National Institutes of Health,
Bethesda, USA). Serum levels of Troponin I were deter-
mined by ELISA (Uscn Life Science Inc., Wuhan, China).
After 30 days, specimens of infarcted myocardium were
obtained after euthanasia, ﬁxed in formaldehyde and
embedded in parafﬁn for histological staining (H&E,
Movat’s pentachrome).
Bari scores for all animals were calculated based on
LAD and LCX pre-occlusion angiograms according to the
method previously described [1, 32].
Quantiﬁcation of cardiac parameters after reperfused
AMI in pigs by magnetic resonance imaging (MRI)
Three and thirty days after the reperfused AMI procedure,
cardiac MRI was performed using a 1.5-T clinical scanner
(Avanto, Siemens, Erlangen, Germany) together with a
phased array coil and a vector ECG system. Cine MR
images were acquired using a retrospectively ECG-gated,
steady-state free precession cine MRI technique in short-
axis and long-axis views of the heart using 1.2 ms echo
time (TE), 40 ms repetition time (TR), 50 ﬂip angle,
300 mm ﬁeld-of-view, 8 mm slice thickness, and
256 9 256 image matrix. Sixteen short-axis images were
acquired using ECG-gated, saturation recovery true fast
imaging with steady-state precession (FISP) sequences.
Delayed enhancement images were obtained after injection
of 0.05 mmol/kg of contrast medium using an inversion
recovery prepared, gradient-echo sequence. Short-axis and
long-axis images were obtained 10–15 min after gadolin-
ium injection. The images were analyzed using Mass 6.1.6
software (Medis, Leiden, The Netherlands). After seg-
mentation of the left ventricular (LV) endocardial and
epicardial borders, end-diastolic and end-systolic volumes
and global LV ejection fraction were automatically calcu-
lated. The left ventricular and infarcted myocardial mass
was determined from the cine and delayed enhancement
MR images, respectively. The infarct size was determined
relative to LV mass. Data analyses and interpretations were
performed by an experienced observer blinded to all study
results.
Human cardiomyocyte culture and immunoblot
analysis
Primary human ventricular cardiac myocytes were
obtained from CellSystems (CellSystems Biotechnologie,
St. Katharinen, Germany) and cultured in cardiac myocyte
medium (CellSystems) at 37C. To investigate the cyto-
protective activity of APOSEC, 3 9 10
5 human cardiac
myocytes were seeded in 6-well plates and cultivated in
either basal medium without serum and growth factors or
in basal medium supplemented with APOSEC (PBMC cell
density, 0.25 9 10
6, 2.5 9 10
6 and 25 9 10
6) for 24 h.
For Western Blot analysis, 3 9 10
5 human cardiac myo-
cytes were incubated with APOSEC (PBMC cell density
for APOSEC production, 2.5 9 10
6) or with lyophilized
UltraCulture Medium for 5, 10, 30 and 60 min and for
24 h. Immunodetection was performed with anti-phospho-
c-Jun (1 lg/ml, New England Biolabs, Beverly, MA,
USA), anti-phospho-CREB (1 lg/ml, New England Bio-
labs, Beverly, MA, USA), anti-phospho-AKT (1 lg/ml,
New England Biolabs, Beverly, MA, USA), anti-phospho-
Erk1/2 (1 lg/ml, New England Biolabs, Beverly, MA,
USA), anti-phospho-Hsp27 (Ser15) (1 lg/ml, New Eng-
land Biolabs, Beverly, MA, USA), anti-phospho-Hsp27
(Ser85), anti-BAG1 (C-16) (1 lg/ml, Santa Cruz Biotech-
nology, Heidelberg, Germany), anti-Bcl-2 (2 lg/ml, Acris,
Herford, Germany), followed by horseradish peroxidase-
conjugated goat anti-rabbit or goat anti-mouse IgG antisera
(both 1:10,000; Amersham BioSciences). In parallel,
identical blots were performed with the equivalent non-
phosporylated factors as controls. In addition, an apoptosis
membrane-array (R&D Systems) was performed with
lysates from cardiac myocytes treated with either medium
or APOSEC (PBMC cell density 2.5 9 10
6) for 24 h
according to the manufacturer’s instructions.
To identify some of the mayor soluble factors that are
responsible for exerting the cytoprotective effect of APO-
SEC or a subset thereof, we sought to inhibit the activity of
selected prominent cytokines by adding neutralizing anti-
bodies. VEGF, IL-8, ENA-78 and MMP9 were selected
based on the higher expression levels over controls and
their known cytoprotective properties. The activity of these
selected factors was blocked using the recommended
concentration of the neutralizing antibodies (2 lg/ml anti-
VEGF: AF-293-NA, 2 lg/ml anti-IL-8: MAB208, R&D
Systems; 2 lg/ml anti-ENA-78: AB-254-PB and 2 lg/ml
anti-MMP9: MAB911; all antibodies obtained from R&D
Systems, USA). Blocking capacity of neutralizing
Basic Res Cardiol (2011) 106:1283–1297 1287
123antibodies was veriﬁed (see Supplementary Fig. 5). Mouse
and goat isotype antibodies were used as controls (Mouse
IgG (Clone 11711), MAB002, Goat IgG, AB-108-C, R&D
Systems). For these neutralization assays, 3 9 10
5 human
cardiac myocytes were incubated with APOSEC and neu-
tralizing antibodies, a combination thereof or with lyoph-
ilized medium for 60 min (for phospho-CREB and
phospho-Hsp-27) or for 24 h (for Bcl-2 and BAG1).
Western blots were performed as described above.
Statistical methods
Statistical analysis was performed using Graph Pad Prism
software (La Jolla, USA). All data are given as
mean ± standard error of the mean (SEM). The Wilcoxon–
Mann–Whitney test or Student’s t test were utilized to
calculate signiﬁcances between the groups. The Bonfer-
roni–Holm correction was used to adjust signiﬁcance levels
for ELISA results. In boxplot ﬁgures, whiskers indicate
minimums and maximums, the upper edge of the box
indicates the 75th percentile and the lower one indicates
the 25th percentile. p values\0.05 were considered sta-
tistically signiﬁcant.
Results
An overview of the study design is shown in Fig. 1 and in a
supplementary video ﬁle (video_aposec.mpg).
Analysis of soluble factors produced by irradiated
human PBMC (APOSEC
H)
To induce apoptosis, PBMC (purity[98%) were c-irra-
diated (60 Gray) and cultured for 24 h. Supernatants of
irradiated and non-irradiated cells were collected and
secreted proteins associated with tissue repair and neo-
angiogenesis were determined by membrane arrays and
ELISA. As shown in Table 1, after irradiation of PBMC,
higher amounts of IL-8, GRO-alpha, ENA-78, RANTES,
Table 1 Analysis of soluble factors secreted by non-irradiated cells and irradiated apoptotic PBMC (APOSEC)
Soluble factors (ng/ml) Viable PBMC Apoptotic PBMC Sig.
1 9 10
6 2.5 9 10
6 25 9 10
6 1 9 10
6 2.5 9 10
6 25 9 10
6
IL-8 1.74 ± 0.40 1.93 ± 0.09 10.49 ± 3.53 1.22 ± 0.29 2.30 ± 0.13 18.01 ± 2.87 ns ns
¥
GRO-alpha 0.17 ± 0.09 0.36 ± 0.09 2.06 ± 1.58 0.07 ± 0.02 0.48 ± 0.09 3.95 ± 0.93 ns ns ns
ENA-78 3.41 ± 1.34 29.93 ± 3.41 34.89 ± 16.33 3.93 ± 1.43 37.86 ± 12.73 108.86 ± 27.88 ns ns
¥
MCP-1 1.66 ± 0.65 0.47 ± 0.21 0.27 ± 0.00 0.76 ± 0.19 0.74 ± 0.17 0.27 ± 0.00 ns ns ns
RANTES 8.32 ± 0.18 18.62 ± 3.21 37.63 ± 2.72 4.01 ± 0.05 22.25 ± 3.64 51.58 ± 4.44 ns ns ns
HMGB1 0.63 ± 0.39 3.44 ± 2.11 33.57 ± 6.45 2.74 ± 0.27 6.46 ± 1.12 20.51 ± 3.62 ns ns

MMP9 4.14 ± 0.91 14.59 ± 2.75 29.46 ± 8.29 0.99 ± 0.16 3.61 ± 0.59 19.35 ± 5.34 ns
,
sICAM-1 0.14 ± 0.04 1.43 ± 0.25 7.43 ± 0.85 0.42 ± 0.25 2.09 ± 0.42 9.40 ± 1.29 ns ns
¥
VEGF165 0.13 ± 0.01 0.42 ± 0.04 0.82 ± 0.34 0.15 ± 0.02 0.64 ± 0.04 4.39 ± 1.22 ns ns
¥
MIF 4.84 ± 0.09 17.79 ± 0.95 13.24 ± 0.85 5.85 ± 0.22 20.15 ± 1.14 58.99 ± 1.17 ns ns
¥
PAI-1 1.25 ± 0.35 1.93 ± 0.29 49.60 ± 9.04 0.00 ± 0.00 5.06 ± 3.25 45.86 ± 1.43 ns ns ns
IL-16 0.0 ± 0.0 0.11 ± 0.02 0.84 ± 0.31 0.00 ± 0.00 1.25 ± 0.07 5.25 ± 0.52 ns
,¥
IL-1ra 0.35 ± 0.09 0.52 ± 0.17 2.16 ± 0.96 0.13 ± 0.04 0.41 ± 0.17 6.43 ± 1.33 ns ns
¥
IL-10 0.01 ± 0.00 0.00 ± 0.0 0.05 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.06 ± 0.01 ns ns ns
IGF-I 0.00 ± 0.00 0.01 ± 0.0 0.03 ± 0.02 0.00 ± 0.00 0.01 ± 0.01 0.03 ± 0.03 ns ns ns
HGF 0.33 ± 0.08 0.16 ± 0.01 0.69 ± 0.19 0.11 ± 0.03 0.07 ± 0.02 0.79 ± 0.19 ns ns ns
FGF-2 0.56 ± 0.02 0.53 ± 0.00 0.59 ± 0.01 0.48 ± 0.01 0.53 ± 0.02 0.55 ± 0.02 ns ns ns
TGF-b 0.08 ± 0.01 0.10 ± 0.01 0.21 ± 0.07 0.06 ± 0.01 0.09 ± 0.02 0.39 ± 0.09 ns ns ns
SDF-1 0.17 ± 0.0 0.19 ± 0.0 0.22 ± 0.03 0.16 ± 0.01 0.15 ± 0.07 0.12 ± 0.04 ns ns ns
G-CSF 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 ns ns ns
GM-CSF 0.00 ± 0.00 0.00 ± 0.00 0.07 ± 0.02 0.00 ± 0.00 0.00 ± 0.00 0.08 ± 0.02 ns ns ns
Cells were incubated in three different cell concentrations for 24 h. Supernatants were analyzed for cytokines, chemokines and growth factors
(n = 5)
ns p[0.05 viable PBMC versus apoptotic PBMC (of corresponding cell density)
 p\0.05 1 9 10
6 viable PBMC versus 1 9 10
6 apoptotic PBMC
 p\0.05 2.5 9 10
6 viable PBMC versus 2.5 9 10
6 apoptotic PBMC
¥ p\0.05 25 9 10
6 viable PBMC versus 25 9 10
6 apoptotic PBMC
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123sICAM-1, MIF, VEGF, IL-1ra and IL-16 were detected in
a cell density-dependent manner as compared to the
supernatant of non-irradiated cells. In contrast, little if any
secretion was detected for MCP-1, IL-10, IGF-1, HGF,
FGF-2, TGF-b, SDF-1, G-CSF and GM-CSF (Table 1),
indicating that some of the factors previously associated
with cardioprotection might not play a relevant role in this
experimental setting [35]. An overview of secreted factors
is shown in Supplementary Fig. 1.
Diverted early inﬂammatory immune response
and long-term preservation of ventricular function
in AMI rats treated with APOSEC
R
Since the degree of the inﬂammatory response after AMI is
an important factor which correlates to infarct size and
outcome, we investigated whether APOSEC
R IV (derived
from rat cells) modiﬁes the extent of necrosis and the
quality of inﬁltrating cells in the ischaemic myocardium.
H&E-staining revealed that rat hearts treated with APO-
SEC
R showed a signiﬁcant reduction of infarction area
within 72 h after ligation of the LAD as compared to
animals receiving medium or the supernatant from viable
cells (Fig. 2a–d).
Compared to APOSEC-treated rats (Fig. 2g), control
AMI animals evidenced a more mixed cellular inﬁltrate in
the wound areas similar to granulation tissue within 72 h
after AMI (Fig. 2e, f). Immunohistochemical analysis
revealed that the cellular inﬁltrate in the APOSEC
R AMI
rats was composed of abundant CD68? monocytes/mac-
rophages (Fig. 2j), signiﬁcantly more than in the control
groups (Fig. 2h, i).
In addition, most of these medium-sized monocytoid
cells in the APOSEC
R cellular inﬁltrate were highly posi-
tive for c-kit (CD117) and vascular endothelial growth
factor receptor 2 (FLK-1) (data not shown) (Fig. 2n).
Expression of both markers was more accentuated in
APOSEC
R-injected rats as compared to control groups (see
representative images, Fig. 2l–o, n = 6 per group). To
further strengthen these histological data, we obtained
hearts 72 h after treatment with either APOSEC
R or control
medium. After homogenisation of myocardium, inﬁltrating
cells were separated and the quantity of c-kit? and CD68?
cells was determined by ﬂow cytometry analysis. Both the
cell populations were enriched in APOSEC
R-injected ani-
mals, as evidenced by a mean increase of 37% of CD68?
cells and 107% of c-kit? cells compared to control animals
injected with medium (n = 4 per group). Figure 2p–r
shows that APOSEC
R-injected rats demonstrate a signiﬁ-
cantly greater extent of viable myocardium within the
anterior free wall of the left ventricle. In contrast, collagen
deposition and scar formation extended through almost the
entire left ventricular wall in rats receiving control medium.
Six weeks after LAD ligation, the mean left ventricular
ejection fractions (LVEF), shortening fractions (SF), left
ventricular end-diastolic diameter (LVEDD) and left
ventricular end-systolic diameter (LVESD) were deter-
mined to be 43.04% ± 4.17 (LVEF), 19.00% ± 2.29
(SF), 10.96 mm ± 0.51 (LVEDD) and 9.00 mm ± 0.63
(LVESD) in animals having received culture medium
alone and 39.38% ± 2.89 (LVEF), 16.88% ± 1.45 (SF),
10.17 mm ± 0.33 (LVEDD) and 8.63 mm ± 0.32
(LVESD) in rats injected with the supernatant of
non-irradiated cells (p values between 0.23 and 0.79).
Remarkably, APOSEC IV-injected AMI rats evidenced
signiﬁcantly improved functional parameters: 56.22% ±
3.05 (LVEF; p = 0.018 vs. medium and p = 0.0006 vs.
viable cell supernatant), 26.33% ± 2.11 (SF; p = 0.016 vs.
medium and p = 0.0018 vs. viable cell supernatant),
9.77 mm ± 0.23 (LVEDD; p = 0.044 vs. medium) and
7.33 mm ± 0.33 (LVESD; p = 0.025 vs. medium and
p = 0.013 vs. viable cell supernatant). Mean levels of
cardiac function of healthy rats without myocardial
infarction were as follows: 60.40% ± 4.95 (LVEF),
29.20% ± 3.26 (SF), 9.00 mm ± 0.55 (LVEDD) and
6.40 mm ± 0.51 (LVESD). Figure 2t, u shows echocar-
diographic data for each group.
APOSEC
P IV protects the myocardium from ischaemic
injury in a pig model of closed chest reperfused AMI
BARI scores did not differ signiﬁcantly between the groups
(see Supplementary Fig. 4), indicating a comparable dis-
tribution of the area a risk after balloon occlusion.
Hearts explanted from animals infused with APOSEC
P
evidenced less myocardial necrosis as shown by tetrazo-
lium chloride staining after 24 h compared to controls
(Fig. 3a–c). Additionally, troponin I release was less than
in animals treated with resuspended lyophilized medium as
controls (Fig. 3d).
Intravenous high-dose APOSEC
P caused a signiﬁcant
short and long-term reduction of myocardial damage as
determined by cardiac MRI (Table 2). These results were
corroborated by a signiﬁcant hemodynamic improvement
as compared to controls. In the high-dose group, APOSEC
infusion reduced the extent of myocardial infarction by
approximately 50%, from 18.17 to 8.66% after 3 days
(p = 0.0019) and from 12.60 to 6.92% after 30 days
(p = 0.015), respectively. Conversely, LVEF, cardiac
output and cardiac index were improved signiﬁcantly
compared to controls or low-dose treatment. Figure 3 (see
also Supplementary Fig. 2 and supplementary video ﬁle)
illustrates representative transverse sections of a high-dose
APOSEC
P-injected animal (Fig. 3h) and a control
(Fig. 3e). H&E-stained (Fig. 3f, i) and Movat’s penta-
chrome-stained (Fig. 3g, j) myocardial specimens obtained
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12330 days after AMI showed less collagen deposition and
more viable myocardium in treated pigs as compared to
controls.
APOSEC
H induces cytoprotective and anti-apoptotic
mechanisms in cardiac myocytes in vitro
Strategies to abrogate the death cascade at the level of
intracellular signalling kinases and inhibitors of apoptosis
were previously deﬁned in the ischaemia–reperfusion (I/R)
and ischaemic postconditioning literature [18, 19, 37, 40],
suggesting that targeting anti-apoptotic mechanisms of
cellular protection at the time of ischaemia may offer a
potential approach for reducing reperfusion-induced myo-
cyte cell death. To investigate whether APOSEC
H is able to
activate pro-survival pathways in cultured cardiac myo-
cytes, we performed Western blot analysis. APOSEC
H
induced phosphorylation of AKT, p42/p44 extra-cellular
signal-regulated kinases (Erk1/2), p38 MAPK, Hsp27,
c-Jun and CREB in human primary cultured cardiomyo-
cytes within 60 min (Fig. 4a) and in dose-dependent
fashion (Fig. 4b). Moreover, the expression of several anti-
apoptotic proteins such as Bcl-2 and BAG1 was up-regu-
lated in APOSEC
H-treated cardiac myocytes after 24 h
(Fig. 4c and Supplementary Fig. 3).
Furthermore, APOSEC
H circumvented cardiomyocyte
cell death in a starvation assay even at low doses such as
APOSEC obtained from 0.25 9 10
6 irradiated apoptotic
PBMC (Fig. 4d). Neutralization of selected factors, e.g.
VEGF, IL-8, ENA-78, MMP9 alone or in combination did
not result in an obvious decrease with regard to CREB and
Hsp27 phosphorylation nor Bcl-2 or BAG1 up-regulation
(Fig. 4e).
Discussion
Current medical and invasive therapies after AMI do not
address the central problem associated with the massive
loss of cardiomyocytes, vascular cells, and interstitial cells,
and in consequence these patients continue to experience
frequent hospitalizations and premature death. Addition-
ally, although reperfusion after coronary occlusion is
undoubtedly prerequisite for tissue salvage, additional
myocardial injury can occur. The sudden reinitiation of
blood ﬂow leads to an inﬂammatory response, which
results in further endothelial and myocardial injury. No
drug has successfully passed clinical trials for cardiac
injury despite the 30 years that have passed since the
phenomenon of ‘‘myocardial injury through reﬂow’’ was
ﬁrst acknowledged [11]. This myocardial reperfusion
injury is triggered by several distinct soluble and/or cellular
components of the inﬂammatory network [12, 23]. In our
previous work we abrogated myocardial remodelling by
infusing cultured irradiated apoptotic PBMC [2, 26] and we
could demonstrate that an alternative approach, namely,
intravenous infusion of soluble factors derived from irra-
diated PBMC (APOSEC) reduced progressive collagen
deposition and scar formation and improved ventricular
function in a rodent model of acute myocardial ischaemia
and in a large animal closed chest reperfused infarction
model.
Recently, there has been a change of thinking in the ﬁeld
of regenerative medicine since publications showed that
soluble factors from bone marrow cells, termed BMC-SN,
initiated proliferation and migration of coronary artery
endothelial cells, endothelial tube formation and cell
sprouting in a mouse aortic ring assay [25]. Other inves-
tigators demonstrated that endothelial progenitor cell-con-
ditioned medium (EPC-CM) enhanced the formation of
capillary outgrowth in a rat aortic ring model and enhanced
survival of serum-starved human umbilical cord endothe-
lial cells (HUVEC) [7]. In vivo relevance was demon-
strated in this study showing that EPC-CM caused
increased blood ﬂow, muscle mitochondrial activity and
functional improvement in an ischaemic hindlimb model.
More recently Kalka et al. have shown that EPC-CM
causes resistance of HUVEC to oxidative stress by induc-
ing anti-oxidative enzymes, and resistance to apoptosis
induction in vitro by increasing the Bcl-2/BAX ratio. From
these results, the group deduced that EPC-CM contains
massive amounts of cytoprotective proteins causing anti-
apoptotic and growth factor-mediated effects. Most
importantly and similar to our results, neutralization of
selective or combined cytokines such as VEGF, HGF, IL-8
and MMP9 did not signiﬁcantly reverse the cytoprotective
effect of EPC-CM. The group concluded that EPC secrete
factors which cause broad synergistic effects and exert
strong cytoprotective properties on differentiated endothe-
lium through modulation of intracellular antioxidant and
defensive mechanisms and pro-survival genes [45].
The mechanism described in the above paragraph for
BMC-SN and EPC-CM is similar to that which we describe
in this paper concerning secreted factors from PBMC,
Fig. 2 Results of in vivo rat experiments. a–d Hearts of APOSEC
R-
injected animals 3 days after LAD ligation evidenced less myocardial
necrosis compared to controls. e–g H&E-stained rat myocardium
3 days after LAD ligation. The cellular inﬁltrate appears to be more
consolidated in APOSEC
R-injected animals. h–j Myocardial tissue
stained for CD68. k Quantiﬁcation of positively stained cells per high
power ﬁeld (HPF). l–n Specimen obtained 3 days after AMI stained
for c-kit, o shows results of cell quantiﬁcation per HPF. p–r shows
size of myocardial infarction 6 weeks after LAD ligation. s Planimet-
ric analyses indicate a signiﬁcant reduction of scar area compared to
controls. t, u show results obtained by echocardiography 6 weeks
after AMI. Functional parameters (SF, LVEDD) were improved in
comparison to medium or viable cell supernatant injected animals
b
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123which documents the ﬁrst evidence that culture medium
from apoptotic PBMC (APOSEC) induces cytoprotective
mechanisms in cultured cardiomyocytes in vitro. However,
unlike the BMC-SN process, which requires bone marrow
stem cell acquisition and preparation, PBMC can be
obtained from venous whole blood, which can be much
more easily obtained via simple venal puncture.
Based on the fact that infarct dimensions were reduced
compared to controls in both in vivo models even within
the ﬁrst 3 days after AMI, we believe that the main
mechanism of action induced by APOSEC treatment is
conferring cardioprotective effects to cardiomyocytes at
risk. In support of this hypothesis, we tested whether
APOSEC could induce the activation of intracellular
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Fig. 3 Results of the porcine closed chest reperfused AMI model.
a, b Show representative images of porcine hearts explanted 24 h
after myocardial infarction stained with tetrazolium chloride and
Evans blue solution. The area at risk is stained red and necrotic areas
remained unstained (white/grey, arrows). c shows the extent of
necrosis for controls and APOSEC
P-treated animals. d shows ELISA
data indicating less troponin I release in treated animals. e, h Show
representative images of hearts explanted 30 days after AMI. Hearts
of APOSEC
P-injected pigs evidenced only marginal formation of scar
tissue in the myocardium compared to control animals where large
infarcts were common. H&E-stained (f, i) and Movat’s pentachrome-
stained (g, j) specimens of the infarcted myocardium shown in the
lower part of Fig. 3 indicate fewer signs of collagen deposition and
more viable cardiomyocytes within the scar tissue (i, j) compared to
control animals (f, g)
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123signalling pathways known to be associated with cardiac
conditioning or cytoprotection [19, 21].
The co-incubation of human cardiac myocytes with
APOSEC led to a rapid phosphorylation of several
important survival factors such as AKT, Erk1/2, p38
MAPK (all part of the ischaemia reperfusion injury salvage
kinase pathway, RISK), c-JUN, cAMP-response element
binding protein (CREB) and Hsp27 [5, 8, 19, 40]. More-
over, Bcl-2 and BAG1, known anti-apoptotic effectors,
were massively enhanced within 24 h.
To identify key factors mediating the cytoprotective
effect of APOSEC, we tried to inhibit the activity of some
factors found in APOSEC at higher concentrations (IL-8,
VEGF, ENA-78, MMP9) by utilizing neutralizing anti-
bodies. As shown in Fig. 4e, the neutralization of these
selected factors alone or in combination thereof was not
sufﬁcient in attenuating the phosphorylation of CREB/
Hsp27 and Bcl-2/BAG1 expression in cultured human
cardiomyocytes exposed to APOSEC. These results sug-
gest that other or even yet unidentiﬁed factors or
combinations thereof or other pleiotropic effects might be
responsible for the beneﬁcial effects seen by APOSEC
treatment.
In addition, as seen in Table 1, we have identiﬁed a
great variety of proteins in APOSEC deﬁned to be relevant
for homing of progenitor cells to sites of ischaemia. We
believe that enhanced presence of c-kit? and CD68? cells
in the infarcted area is a direct consequence of early single-
dose intravenous administration of APOSEC after the onset
of myocardial ischaemia. Based on these ﬁndings, we
suggest that APOSEC IV is causative for myocardial
resistance to hypoxia-induced cell damage in AMI and
circumvented inﬂammation.
According to the guidelines issued by the European
Society of Cardiology and the American Heart Association
(AHA), prompt restoration of coronary perfusion within
the shortest time is currently considered to be the standard
of cardiac care for patients suffering from ST-elevation
myocardial infarction (STEMI) [3, 41]. We therefore have
chosen a similar approach by utilizing a closed chest
Table 2 Cardiac MRI evaluation 3 and 30 days after AMI
Parameters Medium control
(n = 8)
250 9 10
6 apoptotic PBMC
(low-dose APOSEC, n = 7)
1 9 10
9 apoptotic PBMC
(high-dose APOSEC, n = 7)
After 3 days Weight (kg) 31.86 ± 9.1 30.86 ± 1.6 ns 33.33 ± 1.3 ns
Age (days) 90 ± 09 0 ± 0n s 9 0± 0n s
LVEDV (ml) 67.59 ± 2.7 64.19 ± 5.4 ns 63.73 ± 1.6 ns
LVESV(ml) 38.42 ± 2.5 35.96 ± 3.0 ns 33.93 ± 2.1 ns
LVSV (ml) 29.17 ± 1.3 28.23 ± 3.2 ns 29.77 ± 1.8 ns
LVEF (%) 43.38 ± 1.9 43.63 ± 2.8 ns 46.65 ± 2.9 ns
HR/min 111 ± 6 109 ± 5 ns 111 ± 13 ns
CO (l/min) 3.24 ± 0.1 3.03 ± 0.3 ns 3.28 ± 0.3 ns
CI (l/min/m
2) 3.64 ± 0.1 3.59 ± 0.4 ns 3.82 ± 0.4 ns
Infarct % 18.17 ± 1.7 14.01 ± 1.9 ns 8.66 ± 1.5**
After 30 days Weight (kg) 39.43 ± 0.5 37.00 ± 1.9 ns 48.83 ± 0.7***
Age (days) 120 ± 0 120 ± 0 ns 120 ± 0n s
LVEDV (ml) 54.74 ± 4.1 53.43 ± 3.2 ns 65.99 ± 3.5 ns
LVESV(ml) 32.93 ± 4.0 31.89 ± 2.9 ns 28.71 ± 3.5 ns
LVSV (ml) 21.84 ± 1.8 21.54 ± 1.9 ns 37.29 ± 1.7***
LVEF (%) 40.54 ± 3.6 40.64 ± 3.2 ns 57.05 ± 3.3**
HR/min 114 ± 7 108 ± 7 ns 107 ± 5n s
CO (l/min) 2.44 ± 0.1 2.28 ± 0.1 ns 3.98 ± 0.2***
CI (l/min/m
2) 2.46 ± 0.1 2.40 ± 0.1 ns 3.51 ± 0.2***
Infarct % 12.60 ± 1.3 11.50 ± 1.5 ns 6.92 ± 1.4*
Three and 30 days after ischaemia/reperfusion injury, MRI was conducted and parameters of cardiac function were obtained from pigs treated
with low and high-dose APOSEC and from control animals
LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, LVSV left ventricular stroke volume, LVEF left
ventricular ejection fraction, HR heart rate, CI cardiac index, CO cardiac output, ns no signiﬁcance versus control
* p\0.05 versus control
** p\0.01 versus control
*** p\0.001 versus control
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Fig. 4 APOSEC
H induces
cytoprotective protein
expression and activation.
a Cell extracts were prepared
after stimulation with
APOSEC
H or control medium
after the indicated time
intervals. Western blot analysis
showed activation of c-Jun,
CREB, AKT, ERK1/2 and
Hsp27. b shows the dose-
dependent induction of Hsp27
and CREB in cultured
cardiomyocytes. c 24 h after
treatment expression of the anti-
apoptotic proteins Bcl-2 and
BAG1 was analyzed by Western
blotting. Proteins were
normalized to the house-
keeping gene GAPDH. One
representative experiment of
two is shown. d shows a dose-
dependent cytoprotective effect
of APOSEC in a starvation
induced cell death model in
cardiac myocytes. e shows that
neutralization of selected factors
(VEGF, IL-8, ENA-78 and
MMP9) does not attenuate the
induction of CREB and Bcl-2 in
cardiomyocytes by APOSEC
co-incubation
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123reperfused AMI large animal model mimicking the human
AMI scenario with ‘‘primary PCI for coronary occlusion’’.
In addition to this standardized treatment of AMI in
humans, we applied high and low-dose APOSEC 40 min
after starting of the LAD balloon occlusion. These time
intervals were selected to accord with the clinical scenario
of earliest possible intravenous therapy with approximately
30-40 min delay from symptom to ﬁrst needle time. Our
obtained short and long-term MRI results evidenced that
one high-dose APOSEC infusion led to a highly signiﬁcant
improvement of cardiac function and attenuation of myo-
cardial infarction, indicating a dose-dependent effect.
Thus, APOSEC would appear to represent a ‘‘biologi-
cal’’ which prevents experimental myocardial infarction by
causing peri-infarct conditioning and stimulation of
regenerative effects in the hypoxic myocardium.
Conclusion and outlook
Beneﬁciary blood products such as intravenous immuno-
globulin (IVIG), coagulation factors or plasma protein
concentrates have conﬁrmed their clinical value in recent
decades. Unlike these derivatives, APOSEC is a product
made of soluble factors secreted by irradiated PBMC. This
lyophilized ‘‘biological’’ combines the following clinically
favourable features: (a) easily obtainable raw material
(PBMC) for APOSEC production from the blood of heal-
thy donors obviating the need to process cell of diseased
patients avoiding disadvantageous effects such as stem cell
dysfunction or a reduced secretory capacity when using
cells of diseased patients [30]; (b) minimal or no antige-
nicity owing to protein-only content; and (c) ‘‘off the
shelf’’ utilization in the clinical setting of AMI diagnosis
requiring only single-dose administration. We conclude
from our in vitro and in vivo data that APOSEC IV exhibits
the features of a highly effective peri-infarct conditioning
drug compound. Since the effectiveness of APOSEC has
been demonstrated in our pre-clinical studies, the use of
APOSEC with human experimental subjects is warranted.
With regard to the underlying mechanisms, further studies
are necessary to fully understand the mode of action of
APOSEC, and we strongly believe that our present study
can serve as a good basis for such a study in the future.
Limitations
In all three experimental settings (rat AMI model, porcine
reperfused AMI model, in vitro experiments using human
cells), APOSEC was tested in a syngeneic fashion only to
obviate inter-species inﬂuences. However, the composition
of the supernatants and its effects on human cardiac
myocytes in vitro were exclusively analyzed for APOSEC
derived from human cells, any differences in the secretory
capacity of rat or porcine PBMC cannot entirely be ruled
out.
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